A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas

Pituitary

Volumn 15, Issue 1, 2012, Pages 44-49

  Boguszewski, Cesar Luiz ^a   Dos Santos, Carlos Mauricio Correa ^a   Sakamoto, Kelly Suga ^a   Marini, Lilian Cassia ^a   De Souza, Admar Moraes ^a   Azevedo, Monalisa ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Bromocriptine; Cabergoline; Prolactinomas; Valvular heart disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; FEMALE; HEART SIZE; HEART VALVE CALCIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL TENTING AREA; MITRAL VALVE LEAFLET THICKENING; MITRAL VALVE REGURGITATION; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; RISK ASSESSMENT; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PROLACTINOMA;

EID: 84858155956     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0339-7     Document Type: Article

References (27)

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273 (Pubitemid 44079693)
2. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 273-288
3. Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259-265
4. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46 (Pubitemid 46041752)
5. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38 (Pubitemid 46041751)
6. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6-9
7. Valassi E, Klibanski A, Biller BM (2010) Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95:1025-1033
8. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334-336 (Pubitemid 35266254)
9. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC (2009) Bromocriptine use and the risk of valvular heart disease. Mov Disord 24:344-349
10. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, Alonso DR (1986) Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 57:1388-1393 (Pubitemid 16055293)
11. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ, American Society of Echocardiography (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777-802 (Pubitemid 37391035)
12. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11-R14
13. Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr (2008) Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 14:672-677
14. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104-108
15. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA, Klibanski A (2010) Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 72:53-58
16. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62:1864-1869
17. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348-3356
18. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5 (Pubitemid 351969123)
19. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153-157
20. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784
21. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897-902 (Pubitemid 29143128)
22. Peralta C, Wolf E, Alber H, Seppi K, Müller S, Bösch S, Wenning GK, Pachinger O, Poewe W (2006) Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord 21:1109-1113 (Pubitemid 44348515)
23. Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225-1229 (Pubitemid 44563832)
24. Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A (2007) Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234-238 (Pubitemid 46374768)
25. Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E (2007) Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 109:350-353 (Pubitemid 46441644)
26. Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H (2008) Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med 263:90-98
27. Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N, Iwama Y, Daida H, Sakai M, Nakayama T, Mizuno Y (2008) The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23:935-941